In the latest wave of industry competition and realignment, few sectors can survive by relying solely on past achievements. The transition from scale leadership to quality leadership is a challenging yet necessary path, and a critical test that all traditional state-owned pharmaceutical enterprises must face.

Sinopharm Group, a pharmaceutical distribution giant with a market value in the hundreds of billions, has finally emerged from the shadow of its worst-ever financial performance. On March 23, the company released its 2025 annual results, reporting a scenario of "profit growth without revenue growth." Full-year operating revenue reached 575.17 billion yuan, down 1.6% year-on-year, while net profit attributable to shareholders was 7.155 billion yuan, a slight increase of 1.5%.

Despite ongoing structural pressures, this outcome represents a hard-won achievement for Sinopharm Group. In 2024, the company experienced its first simultaneous decline in both revenue and net profit since its 2009 listing, with net profit attributable to shareholders plunging 22.14%, leading to significant growth stagnation. Entering 2025, Sinopharm Group pushed forward with adjustments under pressure: a management reshuffle, the implementation of a ten-billion-yuan strategic cooperation, large-scale closures of retail pharmacies, and a digital transformation initiative. The current results, showing growth against the trend, indicate the company has temporarily steadied its position.

Throughout the year, Sinopharm's performance showed a steady recovery starting in the third quarter. In the first half of 2025, it was the only company among the top four distributors to report a revenue decline, with revenue of 286.043 billion yuan (down 2.95%) and net profit attributable to shareholders of 3.466 billion yuan (down 6.43%). By the third quarter, net profit shifted from decline to growth; towards year-end, further efforts by the new management team contributed to a full-year net profit increase of 3.94% year-on-year.

The pharmaceutical distribution industry is widely recognized as entering a cycle of plateauing growth and thin profit margins. The trend of "larger players growing stronger" continues to intensify, pushing small and medium-sized distributors into an unprecedented survival crisis. The industry is now in a critical phase of deep adjustment and challenging transformation. As the industry leader, what signals does Sinopharm Group's difficult turnaround send?

Sector performance has diverged significantly, with the retail segment becoming the brightest spot. Sinopharm Group operates three main business segments: pharmaceutical distribution, medical device distribution, and pharmaceutical retail, which accounted for 72.79%, 19.32%, and 6.42% of 2025 revenue, respectively. Overall, all three segments are undergoing structural adjustments but exhibit distinct developmental trends.

First, the pharmaceutical distribution segment, which serves as the performance anchor. Under the policy direction of centralized procurement focusing on "price stability and quality improvement," price pressures and market competition have intensified. The segment's annual revenue was 435.39 billion yuan, down 2.02% year-on-year. Viewed over a longer period, this marks the first slight decline for the pharmaceutical distribution business. Before 2023, the segment saw continuous growth; growth slowed noticeably in 2024 but remained slightly positive; in 2025, it entered negative growth for the first time, highlighting the increasing pressure from policies. However, revenue showed a sequential improvement in the second half of 2025, demonstrating strong operational resilience. Through measures like optimizing product mix, enhancing coverage in core regions, and advancing refined customer management, the full-year revenue decline narrowed significantly compared to the 3.52% drop in the first half, indicating a clear trend of quarterly improvement.

Next, the medical device distribution segment. This segment reported annual revenue of 115.54 billion yuan, also down 2.02% year-on-year. Within this, medical consumables achieved stable growth supported by the expansion of primary healthcare and rigid clinical demand. Conversely, revenue from IVD products and medical equipment sales declined, primarily due to price reductions from centralized procurement and normalized compliance supervision, which slowed the pace of equipment replacement and centralized purchasing. In 2025, as profit margins for traditional distribution models continued to narrow, Sinopharm Group undertook deep structural adjustments in its device distribution business. By controlling inefficient operations and focusing on smart supply chain projects like SPD, the segment is transitioning from "scale expansion" to "quality and efficiency." The effects of this adjustment are already visible in the performance. In 2024, segment revenue fell sharply by 9.44%, impacted by changes in end-demand structure and a decline in high-margin product categories; the current narrowed decline indicates the initial success of the structural adjustments.

The most significant operational highlight for the year came from the pharmaceutical retail segment. In 2025, this segment achieved a historic strategic turnaround to profitability. Annual revenue reached 38.38 billion yuan, up 6.67% year-on-year, with its revenue share hitting a three-year high. Over the past year, Sinopharm Group initiated systematic reforms, implementing a combination of strategies including closing inefficient stores, increasing centralized procurement ratios, and deepening wholesale-retail synergy. These adjustments led to a qualitative change in the company's profit structure: Guoda Pharmacy significantly reduced its losses, and specialized pharmacies became the core growth engine. Simultaneously, against the backdrop of the full implementation of policies facilitating the flow of prescriptions from hospitals to retail pharmacies, Sinopharm's wholesale-retail synergy strategy is now entering a phase of value realization.

Notably, the retail pharmacy industry has experienced a massive wave of closures over the past two years. As the national leader, Guoda Pharmacy's store closure actions were particularly pronounced. This wave began in the first half of 2024, when Guoda Pharmacy started closing stores at a relatively measured pace, shutting down 176 directly-operated stores and 67 franchised stores, while maintaining a total store count around ten thousand. The pace accelerated significantly in the second half, with 1,097 directly-operated stores and 322 franchised stores closed, a figure 5.84 times higher than in the first half. In 2025, the company continued to close loss-making stores vigorously. Financial reports show that by the end of the reporting period, Guoda Pharmacy's store count was 8,221, a net reduction of 1,348 stores year-on-year, marking a definitive end to the era of "ten thousand stores." Behind these closure figures lies Sinopharm Group's strategic shift from pursuing scale expansion to improving per-store efficiency, reflecting a rational recalibration by leading chains during an industry shake-up.

Overall, in 2025, Sinopharm Group continued to drive business structure optimization, focusing on high value-added activities and proactively adjusting inefficient operations. From maintaining market share despite the first-ever slight decline in distribution, to seeing initial results from structural adjustments in the device segment, and achieving a historic turnaround in retail, this "profit growth without revenue growth" performance represents a hard-earned result achieved under the dual pressures of industry cyclical challenges and the company's own deep structural adjustments.

However, the underlying weakness in the core business growth of Sinopharm Group has not been fundamentally reversed. Much of the profit increase was achieved through cost-saving measures—cutting inferior assets, reducing expenses, and optimizing liabilities—to buy time for structural adjustment. The path through this cycle remains fraught with challenges.

Is the giant facing a winter? Recently, several listed companies under the Sinopharm Group umbrella have released their 2025 report cards, including Sinopharm Modern, China Traditional Chinese Medicine, Sinopharm Zhiyi, and Sinopharm Co., Ltd. Overall, as a "super giant" spanning the entire industry chain, Sinopharm Group is confronting a growth bottleneck. Most segments experienced varying degrees of growth weakness in 2025, making performance fatigue a core issue the group must now address directly.

The distribution sector as a whole exhibited "profit growth without revenue growth," indicating a relatively stable foundation. Sinopharm Group and Sinopharm Zhiyi are the main players in distribution and retail; both saw slight revenue declines (-1.60%, -1.29% respectively). Although both achieved positive profit growth, particularly Sinopharm Zhiyi with a surge of 76.80%, this was primarily due to factors like reduced asset impairment and lower costs, rather than business expansion. Furthermore, Sinopharm Co., Ltd., the core platform for narcotic and psychotropic drug distribution, reported "revenue growth without profit growth" in 2025. Revenue was 52.47 billion yuan, up 3.70% year-on-year, while net profit attributable to shareholders was 1.997 billion yuan, down 0.18%.

The industrial segment showed severe divergence, with traditional Chinese medicine suffering a particularly sharp setback. Sinopharm Modern, in the chemical pharmaceutical sector, reported declines in both revenue and profit, with revenue of 9.363 billion yuan (down 14.40%) and net profit attributable to shareholders of 944 million yuan (down 12.85%). China Traditional Chinese Medicine reported its first loss in a decade, with revenue falling 10.70% and a net loss attributable to shareholders of 342 million yuan, a rarity in Sinopharm Group's history.

For Sinopharm Group, its current scale advantage has not yet been effectively translated into sustained profit growth. The greatest future challenge will be making the genuine leap from "scale leader" to "quality leader." In this context, the relatively stable performance of Sinopharm Group makes it a noteworthy case study.

In 2025, after three major consolidation waves focused on centralization, the pharmaceutical distribution industry entered a phase of "growth stagnation." Deepening centralized procurement, stricter regulations, and continuously narrowing profit margins constitute challenges all distributors must confront. As the industry leader, Sinopharm Group entered a critical攻坚 year, pushing forward a series of deep adjustments including "management succession, operational model optimization, and digital-intelligent transformation," and upgrading its strategic positioning from a traditional "pharmaceutical and medical device supply chain network operator" to a "digital-intelligent distribution service provider."

In 2025, Sinopharm Group completed a key management transition. In late November, the company announced that Chairman Zhao Bingxiang had resigned from all positions, including non-executive director and chairman, due to work arrangements. Simultaneously, Jin Bin, a veteran of the "Sinopharm system," was elected as the new chairman and authorized representative, and Li Ying was nominated as a non-executive director. The new management quickly established a strategic focus on "value orientation, lean management, and integrated operations," successfully reversing the profit decline seen in the first half of the year.

Concurrently, Sinopharm Group全面推进 integrated operations in procurement, logistics, and management, shifting from a "decentralized management" model to "penetrating control." Specific results include: the rate of unified drug procurement within provinces increased to approximately 55%, a significant rise of nearly 16 percentage points year-on-year, effectively reducing procurement costs and enhancing inventory transparency. Logistics integration consolidated national warehouse resources, leading to a notable decrease in logistics costs. Management adopted a centralized approach, incorporating backend functions of lower-level enterprises into the centralized control of parent companies, strengthening the headquarters' management oversight capabilities.

Furthermore, the company positioned digitalization as the core engine of its transformation. Currently, Sinopharm Group has completed master data governance for all business lines, establishing a comprehensive data management system. It has also fully implemented the collection and uploading of traceability code data for all legal entities involved in the distribution sector's medical insurance traceability requirements. Notably, Sinopharm Group is deepening its engagement upstream, accelerating cooperation with industrial partners, particularly by increasing the introduction of innovative drugs, nationally negotiated drugs, and clinically high-value products. In December, Sinopharm Group renewed a three-year distribution agreement with Fosun Pharma's subsidiary for 12.2 billion yuan.

In summary, in the new round of industry competition and cooperation, few sectors can survive on past glories. In 2025, many traditional state-owned pharmaceutical enterprises entered a painful transition period, where traditional expansion logic is failing, and the industry tide is pushing everyone out of their comfort zones. While the industry winter has not yet fully passed, finding the beacon's direction is the first step. Sinopharm Group's report card of "stabilizing the situation" may well indicate that the guiding light for the journey ahead has begun to shine.